Xeljanz (Tofacitinib) Denied: Appealing JAK Inhibitor Denials for RA, UC, and PsA

Xeljanz (tofacitinib) was the first oral JAK inhibitor approved in the United States, and it remains FDA-approved for moderate-to-severe rheumatoid arthritis, moderately to severely active ulcerative colitis, active psoriatic arthritis, and polyarticular course juvenile idiopathic arthritis. It changed treatment for patients who could not tolerate injectable biologics or who needed an oral option. But following the 2021 FDA safety communication and label updates, Xeljanz has faced an increase in insurance denials — and many of those denials are based on a misapplication of the safety data.

Why Xeljanz Gets Denied

Post-ORAL Surveillance denials. The ORAL Surveillance trial found that tofacitinib (at 5 mg and 10 mg twice daily) was associated with higher rates of MACE, malignancy, and thrombosis compared to TNF inhibitors in RA patients over 50 with additional cardiovascular risk factors. The FDA responded by adding a class-wide black box warning and restricting the 10 mg twice-daily dose for UC to patients who have failed TNF inhibitors. Insurers have used these label changes to deny Xeljanz for patients with any elevated cardiovascular risk — often overinterpreting the data.

Step therapy for RA. Like other biologics, Xeljanz requires documented failure of conventional DMARDs (primarily methotrexate) before approval for RA. Some plans also require prior biologic failure before an oral JAK inhibitor is approved.

UC dose restriction. The FDA restricted the 10 mg twice-daily dose for UC to patients who have failed at least one TNF inhibitor. If a prescriber submits a prior auth for the 10 mg BID dose without documented TNF failure, the insurer will deny. The 5 mg BID dose for UC maintenance does not carry the same restriction, but prescribers need to ensure the submitted dose matches the step in the treatment pathway.

Psoriatic arthritis step therapy. PsA coverage requires documented NSAID and DMARD failure, followed sometimes by required TNF inhibitor failure before an oral JAK inhibitor is approved.

How to Navigate the Safety-Based Denial

When an insurer denies Xeljanz citing the black box warning, the appeal should include:

Individual risk stratification. The ORAL Surveillance trial studied a specific high-risk population: age ≥ 50, with at least one cardiovascular risk factor. If your patient does not fit this profile, the denial based on the warning is overreaching. Document age, smoking status, lipid levels, blood pressure, diabetes status, and personal cardiovascular history.

Comparison to alternatives. If the insurer prefers a TNF inhibitor, but the patient has a specific contraindication to TNF therapy (prior demyelinating disease, heart failure NYHA class III/IV, prior TB without completion of prophylaxis), document these contraindications explicitly.

Failure of prior TNF therapy. If you have already tried a TNF inhibitor and it failed — due to inadequate response, loss of response, or adverse events — document this thoroughly. TNF failure is both a step therapy compliance argument and a clinical rationale for choosing a mechanistically different agent.

Comparison to other JAK inhibitors. The FDA's safety analysis focused primarily on tofacitinib. Some prescribers argue that more selective JAK1 inhibitors like upadacitinib (Rinvoq) or baricitinib (Olumiant) have different risk profiles. However, all JAK inhibitors carry the class-wide warning. If your insurer is denying all JAK inhibitors, your appeal must address the class issue or pivot to a biologic argument.

The Ulcerative Colitis Appeal

For UC specifically, structure your appeal around:

• Documented moderate-to-severe UC (Mayo score, endoscopic findings, CRP/albumin/fecal calprotectin)
• Prior therapies: 5-ASA agents, corticosteroids, azathioprine or 6-MP with outcomes documented
• TNF inhibitor trial (required for 10 mg BID dose): drug name, start/stop dates, reason for discontinuation
• Prescriber rationale for Xeljanz over other UC biologics (vedolizumab, Stelara, ozanimod)

If the insurer requires the 5 mg BID maintenance dose after induction, confirm the prior auth reflects the correct dosing stages.

Fight Back With ClaimBack

Xeljanz denials are often technically based and winnable when the appeal directly addresses the safety profile in the context of your individual patient's risk factors. ClaimBack builds that individualized case efficiently.

Start your Xeljanz appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied